Project Grant R01CA288237
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$553K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award of $509,448.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research to investigate the role of antigen-presenting cells in modulating tumor-specific immune tolerance and metastatic progression. The primary objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development in lymph nodes, and 2) assess therapeutic strategies to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will provide $248,242 to The Regents of the University of California, San Francisco to elucidate the role of the AIRE gene and AIRE-expressing cells in tumor growth and immune evasion. The research aims to define the phenotypic and transcriptional profiles of tumor-associated AIRE-expressing cells, determine the mechanisms by which they promote tumor progression, and identify the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) aims to develop innovative molecular imaging strategies to identify mechanisms of resistance to immunotherapy in cancer patients. The $676,006 award, with a project period from January 1, 2025 to December 31, 2029, will support research to utilize PET imaging, implantable fluorescence sensors, and high-parameter...
The National Cancer Institute awarded a $647,632 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of California, Los Angeles (UCLA) to develop and evaluate "TNF-ALPHA-'ARMED' TCR VECTORS TO ENHANCE ADOPTIVE CELL THERAPY FOR SOLID TUMORS." The project aims to generate novel lentiviral vectors that co-express tumor antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) along with tumor necrosis factor alpha (TNF-alpha) to enhance the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
The National Cancer Institute (NCI) awarded a $179,988 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Leland Stanford Junior University (Stanford University) for the project "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer." The goal is to identify bacterial functions that can enhance response to immune checkpoint blockade (ICB) cancer immunotherapy. The project will leverage metagenomic data analysis, genetic engineering of...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $302,228 project grant to The Regents of the University of California, San Francisco to support research on "Establishing and Overcoming the Mechanisms of Liver Metastasis-Induced Systemic Tumor Immune Tolerance and Immunotherapy Resistance in Melanoma." The 3-year grant project, running from September 30, 2023 to September 29, 2026, will investigate the biological mechanisms by...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $550,255 in funding to The Regents of the University of California, San Francisco (UCSF) to develop and apply a new "structural surfaceomics" technology. This technology aims to systematically identify tumor-specific protein conformations on cell surfaces that could serve as novel immunotherapy targets, with an initial focus on acute myeloid leukemia (AML). The key...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $607,580 to The Regents of the University of California, San Francisco to conduct research focused on understanding and exploiting molecular abnormalities of tumor vasculature. The key objectives are to: Identify molecular markers that can distinguish tumor vasculature from normal vasculature through gene expression analysis and validation. Determine if inhibiting the ENPEP marker of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $680,507 to The Regents of the University of California, San Francisco (UCSF) to elucidate mechanisms that promote cancer cell persistence and identify druggable targets to eliminate these persister cells. The overarching goal is to improve the durability of targeted cancer therapies by preventing the evolution of genetic resistance through the elimination of persister cell...